The raised price target by Morgan Stanley indicates a positive outlook for Gilead Sciences. This could potentially lead to an increase in the stock's price as it suggests that the analyst believes the stock is worth more than its current market price. However, the Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector, indicating a neutral stance.